Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493780 | 0.81 | MAPT (0.56) | THRBTAS1R3TAS1R1TAS1R2RAB9A | |
| SCHEMBL29395986 | 0.81 | MAPT (0.56) | THRBTAS1R3TAS1R1TAS1R2RAB9A | |
| SCHEMBL32670789 | 0.81 | MAPT (0.56) | THRBTAS1R3TAS1R1TAS1R2RAB9A | |
| SCHEMBL4488778 | 0.80 | S1PR3 (0.52) | THRBTAS1R3TAS1R1TAS1R2RAB9A | |
| Cyclohexane SCHEMBL28734369 | 0.78 | MAPT (0.57) | TAS1R3TAS1R1TAS1R2RAB9APOLB | |
| SCHEMBL4763131 | 0.77 | HTT (0.62) | RAB9ANPC1HSD17B10HTTSMN1; SMN2 | |
| SCHEMBL10415432 | 0.77 | GRM4 (0.63) | RAB9ANPC1POLBHTTSMN1; SMN2 | |
| SCHEMBL4490746 | 0.76 | CYP1A2 (0.56) | THRBRAB9ANPC1POLBHSD17B10 | |
| SCHEMBL22257198 | 0.75 | RAB9A (0.52) | THRBTAS1R3TAS1R1TAS1R2RAB9A | |
| SCHEMBL22256792 | 0.75 | RAB9A (0.49) | THRBTAS1R3TAS1R1TAS1R2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1937682-A1 | MET KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | THRB 485/4885TAS1R3 3044/4885TAS1R1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.